Understanding and targeting cancer stemness and immune suppression in advanced gastric cancer

Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinoma

NIH-funded research Coriell Institute for Medical Research · NIH-10933008

This study is looking at how a protein called YAP1 affects advanced stomach cancer, especially in patients with cancer that has spread to the lining of the abdomen, to find new ways to treat this tough condition and help improve outcomes for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCoriell Institute for Medical Research NIH-funded
Lab location1 site (Camden, United States)
Project IDNIH-10933008 on NIH RePORTER

What this research studies

This research investigates the role of YAP1 in advanced gastric adenocarcinoma, particularly focusing on its impact on cancer stemness and immune suppression in patients with peritoneal carcinomatosis. By analyzing patient-derived specimens, the study aims to uncover the molecular mechanisms that contribute to the aggressive nature of this cancer and its resistance to treatment. The researchers will utilize advanced techniques, including single-cell RNA sequencing, to identify potential therapeutic targets that could improve patient outcomes. The ultimate goal is to develop novel treatments that can effectively combat this challenging condition.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with advanced gastric adenocarcinoma, particularly those experiencing peritoneal carcinomatosis.

Not a fit: Patients with early-stage gastric cancer or those without peritoneal carcinomatosis may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for patients with advanced gastric adenocarcinoma.

How similar studies have performed: While the specific approach of targeting YAP1 in this context is novel, similar research has shown promise in other cancer types, indicating potential for success.

Where this research is happening

Camden, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.